Further evaluation of IDO1 inhibitor with clinically manageable safety profile to commence following review of Phase 1 clinical data and trial design Gosselies, Belgium – January 4, 2017  – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that

Presentations to highlight new preclinical results for A 2A  antagonist and TIGIT antibody programs Gosselies, Belgium – November 6, 2017  – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced the presentation of posters on its novel A 2A

Gosselies, Belgium – August 8, 2017  – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announces that Michel Detheux, iTeos’ Chief Executive Officer, will present a company overview at the 2017 Wedbush PacGrow Healthcare Conference on Tuesday, August

Funding will support the clinical development of the Company’s lead innovative immuno-oncology drug Gosselies, Belgium – July 28, 2017  – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announces that it has been granted EUR 7.5 million in non-dilutive

Gosselies, Belgium - April 3, 2017 - iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, will present preclinical data for its A 2A  receptor antagonist, which inhibits the immune suppressive function of adenosine, at the American Association for Cancer Research

Gosselies, Belgium – February 10, 2017 –  iTeos Therapeutics SA, a Belgian privately-held biotechnology company applying its expertise in translational tumor immunology to the development of novel cancer immunotherapies, today announced that Michel Detheux, iTeos’ Chief Executive Officer, will

- Initial goal to determine treatment efficacy of iTeos’ immuno-     oncology drug candidates - Option for iTeos to license Cristal’s proprietary nanotechnology platform for development of up to three immuno-oncology therapeutic candidates Maastricht, The Netherlands and Gosselies, Belgium –

Gosselies, Belgium – November 28, 2016 – iTeos, a biotechnology company applying its expertise in translational tumor immunology to the development of novel cancer immunotherapies, announced today that it has completed the relocation of its 39 employees into a newly rebuilt, 1,500 square meter

Gosselies, Belgium - October 24, 2016 — iTeos Therapeutics S.A, together with ChemCom S.A., ImmunXperts S.A., the de Duve Institute and IRIBHM have been awarded 1,6 million euro grant through a BioWin project called IT-Targets. The aim of this collaboration is to identify innovative drug candidates